Journal article
Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole.
Abstract
564
Background: Our group previously examined if baseline patient/tumor characteristics, or prior treatment affected cause of death in MA.17, a placebo controlled extended adjuvant trial of the aromatase inhibitor (AI) letrozole. We now examine factor effects on all cause mortality in MA.27. Methods: MA.27 was an adjuvant phase III superiority trial of 5 yrs of exemestane vs anastrozole, in ER+ postmenopausal breast cancer …
Authors
Chapman J-AW; Shepherd LE; Ingle JN; Muss HB; Pritchard KI; Gelmon KA; Whelan TJ; Elliott C; Goss PE
Journal
Journal of Clinical Oncology, Vol. 31, No. 15_suppl, pp. 564–564
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2013
DOI
10.1200/jco.2013.31.15_suppl.564
ISSN
0732-183X